期刊
SEMINARS IN CANCER BIOLOGY
卷 64, 期 -, 页码 93-101出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2019.06.012
关键词
Autoimmunity; Immunotherapy; Immune checkpoint inhibitors; Toxicity and irAEs
类别
资金
- American Cancer Society-Melanoma Research Alliance Team Award [MRAT-18-114-01-LIB]
- National Cancer Institute Midcareer Investigator Award in Patient-Oriented Research [K24 CA201543-01]
- V Foundation Robin Roberts Cancer Survivorship Award [DT2019-007]
- Melanoma Research Alliance-Society for Immunotherapy of Cancer Young Investigator Award in Immune-related Adverse Events [619351]
Immune checkpoint inhibitors have emerged as a remarkable treatment option for diverse cancer types. However, a significant number of patients on checkpoint inhibitors develop immune-related adverse events (irAEs) affecting a wide variety of organs. These events, which may reflect enhanced T cell activation, are unpredictable, heterogeneous, and in some instances permanent or life-threatening. It is not clear whether these toxicities are distinct from conventional autoimmune diseases or whether the manifestation of irAEs is associated with therapeutic efficacy. Studies across the spectrum of basic, preclinical and clinical research deciphering the role of genetics, epigenetics, gut microbiota and underlying immune status of patients who develop irAEs are required to gain a deeper mechanistic understanding. Insights gained from such studies will facilitate identification of biomarkers for optimal treatment and clinical management of patients. In this Review, we provide basic and clinical understanding of immune checkpoint inhibitors and irAEs. We discuss the connection between immune system, autoimmunity and cancer; immune checkpoint inhibitors and associated autoimmune toxicities; insights into potential underlying mechanisms of irAEs; impact of autoimmune diagnosis on cancer outcome; and management of irAEs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据